肿瘤细胞治疗研究
ALL SOURCES
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.
我们的研究结果揭示了BNT162b2疫苗在塑造CLL和FL患者微生物组组成方面的作用，尽管这些患者正在接受针对其活动性基础疾病的治疗，并强调了全面分析免疫组和微生物组特征对于理解这些患者队列中免疫功能的重要性。
Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.
抗CD38抗体目前构成了治疗AMR证据最强的药物类别。
Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.
MYC 高表达的肿瘤细胞通过几种互不重叠的机制削弱了治疗性抗体的疗效。
slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis.
我们的观察为slan+单核细胞在抗体依赖性肿瘤细胞靶向中发挥的细胞毒性机制提供了新的见解，并增进了我们对如何扩展癌症治疗武器库的认识。
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
用双特异性抗体结合 NKG2D，对于直接激活细胞毒性淋巴细胞，或支持单克隆抗体或双特异性 T 细胞衔接器对其的激活，具有吸引力。
Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer Patients.
小细胞肺癌（SCLC）约占肺癌病例的10%至15%。
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
免疫疗法开启了癌症治疗的新纪元。
The evolution of bispecific antibodies in multiple myeloma.
多发性骨髓瘤（MM）的治疗在过去十年中发生了革命性变化，随着靶向CD38的单克隆抗体如达雷妥尤单抗和伊沙妥昔单抗的问世，这些药物已被整合到新诊断或复发和/或难治性（R/R）MM患者的治疗武器库中。
Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a
肾移植晚期或慢性抗体介导的排斥反应尚无既定治疗方法。
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech
在该队列的 606 例患者中，96 例（16%）感染了 COVID-19，中位时间为 Evusheld 给药后 98.5 天。
MEMBER ACCOUNT
登录成功会直接打开下一页。
